Liquidia Technologies, which is seeking a listing in Singapore, is said to be in talks with Khazanah Nasional Bhd to sell a stake in the biopharmaceutical company, Bloomberg reports.
The news wire reported on Friday that Liquida was seeking a valuation of US$300mil for its listing on Singapore's Catalist Market in 2017.
Recently, the Bill & Melinda Gates Foundation made a US$10mil programme-related investment (PRI) in the company to support the development and commercialisation of safer and more effective vaccines and therapeutics.
The foundation said on its website the investment followed recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative (MVI).
Liquidia Technologies transforms the development of new therapies by precisely engineering drug particles.
It said its proprietary PRINT technology solves common problems with drug delivery and efficacy.
This technology is a scalable cGMP compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration.
Hot Stocks for Intra & Contra Day Trader in SGX Market
CAPITALAND
THAIBEV
ALLIANCE MINERALS
So Earn more trade on These Stocks . . . . . .
Today Recommendations :
MMFS SG INTRADAY SIGNAL: BUY AA AT 0.041 TARGET 0.043, 0.045 SL 0.038
No comments:
Post a Comment
Note: only a member of this blog may post a comment.